Cetero Research
From Wikipedia, the free encyclopedia
[edit] Overview
In late 2006, PRACS Institute, Gateway Medical Research and Ba Research International joined together to form Cetero Research, a contract research organization (CRO) serving the biotechnology, generic, and pharma industries.
The name Cetero is derived from the Latin phrase de cetero, meaning for the future. It captures the purpose and philosophy of the new company – to contribute to the future of individuals, families and the healthcare system by conducting rigorous, accurate and timely pharmaceutical research.
Cetero Research specializes in early clinical research and bioanalysis. With more than 23 years of experience, Cetero provides practical solutions for Bioequivalence, Cardiac Safety, Dermatology, Bioanalytical and Labeling support studies.
Cetero has clinical locations in Fargo, ND, East Grand Forks, Minnesota and St. Louis, Missouri. Their bioanalytical operations are based in Houston, TX, Fargo, ND and Toronto, Canada.
[edit] Major services & products/markets served
Integrated Bioequivalence Studies Cetero’s Integrated Bioequivalence Solution links clinical, pharmacokinetic, bioanalytical and statistical services in a seamless package.
Bioanalytical Studies With more than 600 available assays, Cetero specializes in analyzing biological samples from Bioavailability, Bioequivalence and clinical trial studies
Cardiac Safety Studies Cetero Research provides companies with the ability to accurately evaluate the potential for unintended effects of drugs on the heart. Specializing in the design, conduct and analysis of cardiac safety studies, Cetero has dosed more than 2,000 participants in Definitive QTc studies since January 2005.
Labeling Support Studies Cetero Research is the specialist in conducting research that is used as the basis for labeling claims. Regularly conducted studies include: • Drug-Drug Interaction • Drug-Food Interaction • Absolute Bioavailability • Dose tolerance escalation • Age/Gender
Dermatology Studies The Cetero team is the recognized leader in the field of dermatological pharmacokinetics and toxicokinetics. The methods utilized have set the industry standard for studying percutaneous penetration in-vitro as well as in-vivo.
